Actelion's diarrhea drug hops on the FDA fast track

The FDA has granted its fast-track status to Actelion's ($ATLN) Phase III drug for C. difficile-related diarrhea, promising a shorter path to approval for the antibiotic treatment. The drug, cadazolid, is in the midst of two late-stage studies on more than 1,000 patients, with results expected in 2016, Actelion said. Under the fast-track rules, the FDA will grant a shortened 9-month review process if the drug meets its endpoints. News

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.